BeyondSpring Past Earnings Performance
Past criteria checks 0/6
BeyondSpring has been growing earnings at an average annual rate of 15.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 47.6% per year.
Key information
15.4%
Earnings growth rate
25.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 47.6% |
Return on equity | n/a |
Net Margin | -829.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
Jun 21BeyondSpring, Beyond Salvage
Feb 03Circling Back On BeyondSpring
Nov 16Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns
Sep 18BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk
Sep 07BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Aug 01BeyondSpring EPS misses by $0.04
Jun 16BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia
Jun 07FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%
Jun 01BeyondSpring EPS misses by $0.17
Apr 30How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?
Dec 22BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution
Dec 15BeyondSpring slides 9% on public offering pricing at $10.0/share
Nov 19BeyondSpring under pressure on shares offering
Nov 17BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial
Nov 16Revenue & Expenses Breakdown
How BeyondSpring makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2 | -16 | 9 | 10 |
31 Mar 24 | 2 | -18 | 10 | 12 |
31 Dec 23 | 2 | -21 | 10 | 15 |
30 Sep 23 | 2 | -24 | 10 | 18 |
30 Jun 23 | 2 | -28 | 11 | 21 |
31 Mar 23 | 1 | -30 | 12 | 23 |
31 Dec 22 | 1 | -33 | 13 | 26 |
30 Sep 22 | 1 | -35 | 15 | 26 |
30 Jun 22 | 1 | -46 | 23 | 28 |
31 Mar 22 | 1 | -56 | 28 | 33 |
31 Dec 21 | 1 | -64 | 31 | 37 |
30 Sep 21 | 1 | -72 | 36 | 40 |
30 Jun 21 | 1 | -68 | 33 | 40 |
31 Mar 21 | 1 | -62 | 26 | 39 |
31 Dec 20 | 0 | -61 | 23 | 42 |
30 Sep 20 | 0 | -57 | 15 | 46 |
30 Jun 20 | 0 | -52 | 11 | 45 |
31 Mar 20 | 0 | -47 | 10 | 39 |
31 Dec 19 | 0 | -38 | 9 | 31 |
30 Sep 19 | 0 | -38 | 9 | 31 |
30 Jun 19 | 0 | -44 | 8 | 38 |
31 Mar 19 | 0 | -49 | 7 | 44 |
31 Dec 18 | 0 | -55 | 6 | 52 |
30 Sep 18 | 0 | -56 | 5 | 54 |
30 Jun 18 | 0 | -57 | 7 | 55 |
31 Mar 18 | 0 | -58 | 9 | 56 |
31 Dec 17 | 0 | -92 | 9 | 89 |
30 Sep 17 | 0 | -80 | 8 | 77 |
30 Jun 17 | 0 | -67 | 5 | 65 |
31 Mar 17 | 0 | -58 | 3 | 56 |
31 Dec 16 | 0 | -12 | 2 | 10 |
30 Sep 16 | 0 | -10 | 2 | 9 |
30 Jun 16 | 0 | -9 | 2 | 8 |
31 Mar 16 | 0 | -8 | 1 | 6 |
31 Dec 15 | 0 | -8 | 1 | 6 |
Quality Earnings: BYSI is currently unprofitable.
Growing Profit Margin: BYSI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BYSI is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: BYSI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.